Alimera Sciences, Inc. announced the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhney will fill the position vacated by long term board member, Dr. Brian K. Halak.

Dr. Sawhney has served as Chief Financial Officer of Garuda Therapeutics, Inc, since September 2022. From May 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA-based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to February 2020, Dr. Sawhney served at KKR & Co.

Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investm ents across private and growth equity in the healthcare sector. From August 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney has also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med-tech and digital health sectors.

Dr. Sawhney holds an M.D. from Harvard Medical School and a BA in Economics from Stanford University. On February 24, 2023, Dr. Brian K. Halak notified Alimera Sciences, Inc. (the “Company”) that he had decided to resign from the Company's Board of Directors (the “Board”), effective upon the appointment of Dr. Roger Sawhney to the Board, which occurred on February 25, 2023. Dr. Halak served as a director of the Company from 2004 until his resignation and he served as a member of the audit committee and the nominating and corporate governance committee of the Board.

Dr. Halak's decision was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices. On February 25, 2023, based in part upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Roger A. Sawhney, M.D. to the Board as a Class III director, to serve until the Company's annual meeting of stockholders in 2025. Dr. Sawhney filled the vacancy on the Board created by Dr. Halak's resignation.

The Board also appointed Dr. Sawhney to replace Dr. Halak on the Board's Audit Committee and Nominating and Corporate Governance Committee.